Sigma Planning Corp Trims Stake in Pfizer Inc. (NYSE:PFE)

Sigma Planning Corp decreased its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 9.6% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 151,530 shares of the biopharmaceutical company's stock after selling 16,023 shares during the period. Sigma Planning Corp's holdings in Pfizer were worth $4,020,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Retirement Wealth Solutions LLC bought a new stake in shares of Pfizer in the 4th quarter worth approximately $26,000. Gladius Capital Management LP boosted its position in shares of Pfizer by 102.8% in the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company's stock worth $30,000 after purchasing an additional 38,015 shares in the last quarter. Sierra Ocean LLC bought a new stake in shares of Pfizer in the 4th quarter worth approximately $34,000. Teachers Insurance & Annuity Association of America bought a new stake in shares of Pfizer in the 3rd quarter worth approximately $35,000. Finally, Joseph Group Capital Management boosted its position in shares of Pfizer by 168.3% in the 3rd quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company's stock worth $36,000 after purchasing an additional 771 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Price Performance

NYSE PFE opened at $26.32 on Friday. The business's fifty day moving average price is $26.30 and its 200-day moving average price is $27.41. The stock has a market capitalization of $149.14 billion, a price-to-earnings ratio of 18.66, a PEG ratio of 0.64 and a beta of 0.64. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.15. The firm had revenue of $17.76 billion for the quarter, compared to analysts' expectations of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company's revenue was up 24.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.10 EPS. On average, equities analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.54%. This is a positive change from Pfizer's previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. Pfizer's dividend payout ratio is 121.99%.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Guggenheim reissued a "buy" rating and issued a $33.00 price target on shares of Pfizer in a research report on Monday, February 10th. Truist Financial lowered their price objective on Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a research report on Wednesday, December 18th. Bank of America reaffirmed a "neutral" rating and issued a $29.00 price objective on shares of Pfizer in a research report on Tuesday, December 10th. Citigroup lowered their price objective on Pfizer from $30.00 to $29.00 and set a "neutral" rating on the stock in a research report on Tuesday, January 28th. Finally, Evercore ISI raised Pfizer to a "strong-buy" rating in a research report on Wednesday, October 30th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $31.92.

Insider Transactions at Pfizer

In related news, Director Ronald E. Blaylock acquired 19,457 shares of Pfizer stock in a transaction dated Thursday, February 13th. The stock was purchased at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now directly owns 27,707 shares of the company's stock, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. 0.06% of the stock is currently owned by company insiders.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.